Logistic regression analyses of clinical features in HH subtypes compared with HFE probands
| Clinical feature and model . | Odds ratio (95% CI) with HFE proband as the reference group . | ||
|---|---|---|---|
| HJV/HAMP . | TFR2 . | HFE nonproband . | |
| Cardiac involvement | |||
| 1 | 11.6 (6.4-21.2)*** | 4.9 (1.6-14.6)** | 0.36 (0.15-0.92)* |
| 2 | 31.3 (10.1--96.9)*** | 7.1 (1.9-26.7)** | 0.67 (0.25-1.8) |
| Hypogonadism | |||
| 1 | 12.0 (7.2-20.2)*** | 3.9 (1.7-9.0)** | 0.46 (0.29-0.72)** |
| 2 | 19.4 (7.8-48.2)*** | 5.2 (1.8-15.3)** | 1.1 (0.62-1.8) |
| Diabetes/hyperglycemia | |||
| 1 | 3.8 (2.1-6.8)*** | 2.4 (0.96-6.2) | 0.23 (0.12-0.44)*** |
| 2 | 8.4 (3.1-23.1)*** | 3.8 (1.2-12.7)* | 0.44 (0.22-0.91)* |
| Skin pigmentation | |||
| 1 | 6.0 (3.3-11.1)*** | 1.8 (0.73-4.4) | 0.43 (0.30-0.63)*** |
| 2 | 12.4 (4.8-32.2)*** | 3.1 (0.93-10.4) | 1.1 (0.68-1.70) |
| Arthritis/arthropathy | |||
| 1 | 0.47 (0.26-0.86)* | 0.85 (0.38-1.9) | 0.45 (0.33-0.61)*** |
| 2 | 1.2 (0.54-2.6) | 1.1 (0.40-2.9) | 0.77 (0.53-1.1) |
| Liver fibrosis/cirrhosis | |||
| 1 | 3.4 (1.7-6.5)*** | 3.1 (1.0-9.4)* | 0.32 (0.22-0.47)*** |
| 2 | 3.0 (0.99-8.8) | 1.9 (0.47-7.9) | 0.55 (0.34-0.88)* |
| Clinical feature and model . | Odds ratio (95% CI) with HFE proband as the reference group . | ||
|---|---|---|---|
| HJV/HAMP . | TFR2 . | HFE nonproband . | |
| Cardiac involvement | |||
| 1 | 11.6 (6.4-21.2)*** | 4.9 (1.6-14.6)** | 0.36 (0.15-0.92)* |
| 2 | 31.3 (10.1--96.9)*** | 7.1 (1.9-26.7)** | 0.67 (0.25-1.8) |
| Hypogonadism | |||
| 1 | 12.0 (7.2-20.2)*** | 3.9 (1.7-9.0)** | 0.46 (0.29-0.72)** |
| 2 | 19.4 (7.8-48.2)*** | 5.2 (1.8-15.3)** | 1.1 (0.62-1.8) |
| Diabetes/hyperglycemia | |||
| 1 | 3.8 (2.1-6.8)*** | 2.4 (0.96-6.2) | 0.23 (0.12-0.44)*** |
| 2 | 8.4 (3.1-23.1)*** | 3.8 (1.2-12.7)* | 0.44 (0.22-0.91)* |
| Skin pigmentation | |||
| 1 | 6.0 (3.3-11.1)*** | 1.8 (0.73-4.4) | 0.43 (0.30-0.63)*** |
| 2 | 12.4 (4.8-32.2)*** | 3.1 (0.93-10.4) | 1.1 (0.68-1.70) |
| Arthritis/arthropathy | |||
| 1 | 0.47 (0.26-0.86)* | 0.85 (0.38-1.9) | 0.45 (0.33-0.61)*** |
| 2 | 1.2 (0.54-2.6) | 1.1 (0.40-2.9) | 0.77 (0.53-1.1) |
| Liver fibrosis/cirrhosis | |||
| 1 | 3.4 (1.7-6.5)*** | 3.1 (1.0-9.4)* | 0.32 (0.22-0.47)*** |
| 2 | 3.0 (0.99-8.8) | 1.9 (0.47-7.9) | 0.55 (0.34-0.88)* |
Logistic regression models were fit to examine how either the genetic form of HH (HFE, HJV/HAMP, or TFR2) and, in the case of HFE HH, whether being a proband or nonproband is associated with a clinical feature, using 2 models: not adjusting for any variables and adjusting for age group (<25, 25-34, 35-44, 45-54, and 55+ years), sex, and log SF. In this analysis, patients with missing data for a particular clinical feature were excluded. Statistically significant differences are denoted as ***P < 0.001, **P < 0.01, *P < 0.05.